Compare CRL & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | HALO |
|---|---|---|
| Founded | 1947 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 8.8B |
| IPO Year | 1999 | 2001 |
| Metric | CRL | HALO |
|---|---|---|
| Price | $169.58 | $63.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $200.09 | $78.18 |
| AVG Volume (30 Days) | 761.0K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.56 |
| Revenue | ★ $1,857,601,000.00 | $151,862,000.00 |
| Revenue This Year | $0.99 | $28.24 |
| Revenue Next Year | $3.26 | $12.79 |
| P/E Ratio | ★ N/A | $24.64 |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $91.86 | $47.50 |
| 52 Week High | $228.88 | $82.22 |
| Indicator | CRL | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 43.61 |
| Support Level | $166.86 | $61.28 |
| Resistance Level | $182.76 | $65.40 |
| Average True Range (ATR) | 7.16 | 1.64 |
| MACD | 2.31 | 0.41 |
| Stochastic Oscillator | 66.74 | 53.58 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.